A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models

BMC Immunology

Proceedings

Mildrey Fariñas¹  Gemma Año¹  Luis G García¹  Luis A Riverón¹  Maria A Padrón¹  Michel Acosta¹  Rubén A Cabrera¹  Sonsire Fernández¹  Maydelis Álvarez¹  Kirenia Blaín¹  Esther M Fajardo¹  Aleida Mandiarote¹  Concepción Campa¹  José L Pérez¹  Daniel Cardoso¹ 

[1] Research & Development Vice-presidency, Finlay Institute, Havana, Cuba;

关键词: Pertussis;    Aluminum Hydroxide;    Neisseria Meningitidis;    Bordetella Pertussis;    Whooping Cough;   

DOI  :  10.1186/1471-2172-14-S1-S8

来源: Springer

【 摘 要 】

Whooping cough remains a health problem despite high vaccination coverage. It has been recommended that development of new strategies provide long-lasting immunity. The aim of this work was to evaluate the potential of proteoliposomes (PL) extracted from Bordetella pertussis as a vaccine candidate against whooping cough. The size of the B. pertussis PL was estimated to be 96.7±50.9 nm by Scanning Correlation Spectroscopy and the polydispersity index was 0.268. Western blots using monoclonal antibodies revealed the presence of pertussis toxin, pertactin, and fimbriae 3. The Limulus Amebocyte Lisate (LAL) assay showed endotoxin levels lower than those reported for whole cell pertussis licensed vaccines, while the Pyrogen Test indicated 75 ng/mL/Kg. The PL showed high protection capacity in mouse challenge models. There was 89.7% survival in the intracerebral challenge and total reduction of the number of CFU in the intranasal challenge. No significant differences (p>0.05) were observed between mice immunized with B. pertussis PL and the Cuban DTwP vaccine, whichever challenge model used. These results encouraged us to continue the development of the B. pertussis PL as a component of a new combined vaccine formulated with tetanus and diphtheria toxoids or as a booster dose for adolescents and adults.

【 授权许可】

CC BY   
© Fernández et al; licensee BioMed Central Ltd. 2013